Results 71 to 80 of about 1,394,911 (165)

Real‐world evidence on the safety and effectiveness of thrombopoietin receptor agonists in aplastic anaemia: A descriptive study using Japanese hospital administrative data

British Journal of Haematology, EarlyView.
Kayoko Mizuno, Yutaka Shimazu, Toshiki Fukasawa, Satoru Ito, Yukihiro Nishio, Mami Shimizu, Koji Kawakami   +6 more
wiley   +1 more source

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 10, Page 2571-2580, October 2026.
ABSTRACT Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive ...
Yifan Han, Ning Lin, Jinghang Xu, Sikui Wang, Jinglan Jin, Jia Shang, Yongning Xin, Youwen Tan, Dazhi Zhang, Jinlin Hou, Ping An, Wen Xie, Yujuan Guan, Qingfang Xiong, Hong Wu, Huiguo Ding, Yu Chen, Rongkuan Li, Zhili Wen, Mingqin Lu, Jinhui Yang, Zhongyin Zhou, Yongjian Zhou, Zujiang Yu, Kecan Lin, Wei Wang, Yan Huang, Yuemin Nan, Xinhua Luo, Rongshu Shi, Yi Kang, Tao Han, Shiyan Chen, Kai Wang, Yunfeng Shan, Jiaping Li, Pingguo Liu, Zheng Lu, Jun Chen, Zhen Liu, Liaoyun Zhang, Li Yang, Jifang Sheng, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu   +45 more
wiley   +1 more source

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice

Hematology Reports, 2015
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis.
Monica Carpenedo, Silvia Cantoni, Veronica Coccini, Marilena Fedele, Enrica Morra, Enrico Maria Pogliani   +5 more
doaj   +1 more source

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

American Journal of Hematology, Volume 101, Issue 12, Page 2957-2960, December 2026.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority EBMT‐SAAWP RACE Study

American Journal of Hematology, Volume 101, Issue 10, Page 2520-2532, October 2026.
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2‐year analysis of this prospective randomized phase III study.
Antonio M. Risitano, Simona Iacobelli, Austin Kulasekararaj, Marleen van Os, Sofie R. Terwel, Joe Tuffnell, Brian Piepenbroek, Morag Griffin, Constantijn J. M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan Carlos Vallejo, Beatrice Drexler, Jean‐Baptiste Mear, Roochi Trikha, Shreyans Gandhi, Anna Maria Raiola, L. G. M. Daenen, Marco R. de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda, Isabel Sánchez‐Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Camilla Frieri, Talha Munir, Jennifer M. L. Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob R. Passweg, Gérard Socié, Ghulam J. Mufti, Carlo Dufour, Régis Peffault de Latour, Severe Aplastic Anaemia Working Party of the EBMT   +52 more
wiley   +1 more source

Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia

, 2021
In the last decade, improvements in genetic testing have revolutionized the molecular diagnosis of inherited thrombocytopenias (ITs), increasing the spectrum of knowledge of these rare, complex and heterogeneous disorders.
José Ramón Gonzalez-Porras, María Luisa Lozano, José María Bastida, José Rivera   +3 more
core   +1 more source

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism [PDF]

, 2020
The manuscript of a paper entitled "Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism".
Anton, Bashilov, Sergei, Gavryushov, Nikolay, Kuzmich, Boris, Izotov, Konstantin, Cherashev-Tumanov, Tatyana, Burykina   +5 more
core   +2 more sources

Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management

Frontiers in Immunology
Cancer treatment-induced thrombocytopenia (CTIT) is a common adverse effect in malignant tumor patients, significantly increasing the risk of bleeding and negatively impacting treatment efficacy and quality of life.
Xutong Zhao, Xiu Shan, Shaofeng Sui, Qinghao Song, Miao Cheng, Yi Zhao   +5 more
doaj   +1 more source